Tirzepatide (TZP) , a novel, once weekly, dual GIP/GLP-1 receptor agonist, is being developed as a glucose lowering agent in type 2 diabetes (T2D) . In the SURPASS clinical trial program, TZP demonstrated significant HbA1c and body weight reductions vs. placebo and active comparators. This post-hoc analysis assessed the relationship between HbA1c and body weight reductions with TZP treatment (5, or 15 mg) . HbA1c and body weight data at 40 weeks (SURPASS-1, -2 and -5) and 52 weeks (SURPASS-3 and -4) were analyzed by trial, due to differences in design, background therapy, and baseline characteristics of participants. Across the trials, HbA1c reductions from baseline were observed in 96-99%, 98-99% and 94-99% of participants treated with TZP 5, and 15 mg, respectively. Moreover, 87-94%, 88-95% and 88-97%, respectively, also experienced weight loss. Significant correlations between HbA1c and body weight changes were observed with TZP in SURPASS-2, -3, -4 (all doses) and -5 (TZP 5 mg only) (statistically significant correlation coefficients ranged from 0.1438 to 0.3130 across studies; p≤0.038, for all doses) . Consistent reductions in HbA1c and body weight, even when used with medications associated with weight gain, were observed in the vast majority of participants treated with TZP at doses of 5, 10, or 15 mg.

graphic
View largeDownload slide
Disclosure

S.Pedersen: Advisory Panel; Abbott Diabetes, AstraZeneca, Bausch + Lomb, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, HLS Therapeutics Inc., Janssen Global Services, LLC, Novo Nordisk, Consultant; AstraZeneca, Bausch + Lomb, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, HLS Therapeutics Inc., Janssen Global Services, LLC, Novo Nordisk, Research Support; AstraZeneca, Eli Lilly and Company, Novo Nordisk, Pfizer Inc., Prometric, Speaker's Bureau; Abbott Diabetes, AstraZeneca, Bausch + Lomb, Bayer AG, Boehringer Ingelheim International GmbH, Dexcom, Inc., Eli Lilly and Company, HLS Therapeutics Inc., Janssen Global Services, LLC, Novo Nordisk. G.E.Umpierrez: Research Support; AstraZeneca, Dexcom, Inc., Novo Nordisk. F.Giorgino: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Consultant; Lilly Diabetes, Sanofi, Research Support; Lilly Diabetes, Roche Diabetes Care, Takeda Pharmaceutical Company Limited. Á.Rodríguez: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. V.Thieu: None. H.Sapin: Employee; Eli Lilly and Company. L.Fernandez lando: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. C.A.Karanikas: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. J.I.Kiljanski: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company.

Funding

Eli Lilly and Company

© 2022 by the American Diabetes Association
2022
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.